Benzinga
Benzinga
Benzinga
lunes, septiembre 14

AbbVie Inc

ABBVNYSE
Trade with Public
Trade with Public
$257.12
2.120.83%
al cierre: Sep 11, 5:00 PM EST
$257.60
0.480.19%
After hour: Sep 11, 5:10 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararInforme de acciones

AbbVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbbVie (ABBV).

Price Target Range — 7 Quarters

Analyst Consensus — 25 Analysts

21Buy
4Hold
Consensus RatingBuy# Analysts25Avg. Consensus PT$265Upside to Avg. PT+2.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 10, 2026HSBCRajesh KumarPT RaiseBuy$300→$315
Aug 20, 2026Piper SandlerDavid AmsellemPT RaiseOverweight$298→$303
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HSBC Maintains Buy on AbbVie, Raises Price Target to $315

HSBC analyst Rajesh Kumar maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $300 to $315.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $298 to $303.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.
Benzinga Newsdesk

PRO
Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target

Wolfe Research analyst Alexandria Hammond upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.
Benzinga Newsdesk

PRO
BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247

BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved